According to World Health Organization (WHO) estimation, 10% of the global population has some form of disability due to different causes; in India, it is 3.8% of the population. Nearly 15-20% of the total physically handicapped children suffer from Cerebral Palsy (CP). For India, the estimated incidence is around 3/1000 live births; however, being a developing country, the expected actual figure may be much higher. Despite the advancement in modern technology and improved neonatal care, stagnant or increasing incidence of CP has been observed, which is of great concern. As far as management or preventive aspect is concerned, no satisfactory criteria have been developed to date. The present study is based on a positive hypothesis for the efficacy of Ayurvedic treatment. The study was carried out in 16 patients, 8 in each group, namely group A (Shashtika Shali Pinda Sweda externally and Samvardhana Ghrita internally) and group B (Samvardhana Ghrita internally) for 35 days duration. In group A, moderate improvement, mild improvement, and no improvement were observed in 50%, 37.5% and 12.5% of patients respectively. In group B, moderate improvement and mild improvement were observed in 75% and 25% of the patients respectively. Statistical significance of results on selected criteria showed the efficacy of the selected Ayurvedic treatment modality in relieving the signs and symptoms of CP. Although it is incurable, Ayurvedic science can provide a better direction by improving the quality of life of children with CP with better life expectancy.

Background:Cerebral palsy (CP) is a leading cause of childhood disability affecting function and development. The global incidence of CP is 2:1000. It has been reported that children with CP and their caretaker have impaired health-related quality of life (QOL). Of the many types and subtypes of CP, none has any known cure. For a detailed description of the disease CP, though, there is no one to one correlation in Ayurvedic classics; it can be taken as Vata Vyadhi as far as its etiology and symptomatology are concerned.Aim:To assess the effect of certain Panchakarma procedures in the management of CP.Materials and Methods:Total 8 patients were registered and treated with 5 days of Udvartana, 5 days of Abhyanga followed by Sarvanga Swedana and then 8 days of Yoga Basti. The same course of treatment has been repeated for 3 times with an interval of 14 days. Ashtanga Ghrita was given during whole procedures as internal medication. Results of treatment were assessed with anthropometrical measurement, developmental milestone, Modified Ashworth Scale, spasm scale, reflex scale, and muscle power grading.Result:This Ayurvedic management shows good result in CP patients, especially by improving growth (height, weight, chest circumference) and development (head holding and sitting), reducing spasticity of left upper limb and muscle spasm.Conclusion:Multisystem approach is needed to improve the condition of the patient. Panchakarma along with internal medication should be given to improve all the facets of spastic CP. Yoga Basti acts by their own mode of action and can be used freely for such disease conditions.

The present single-centered randomized control trial (RCT) was carried out with the prime aim of assessing the effect of Kasahara Dashemani Vati (trial drug) on Kasa and Vyadhikshamatva in the children suffering from recurrent respiratory tract infections and comparing it with the efficacy of Indukanta Vati. The clinical trial included 40 patients belonging to age group of 3-12 years. The drugs were administered in a daily dose fixed as per “Clark's Rule” along with honey for duration of 60 days. The effect of treatment on the signs and symptoms of Kasa was assessed on the 15th day, whereas the effect on Vyadhikshamatva was assessed on the 60th day. The patients were under follow-up for a period of 60 days after completing the treatment course for evaluation of any recurrence. Effect of the therapy on the individual signs and symptoms of Kasa, laboratory parameters, immunoglobulin (Ig) biomarkers, status of Atura Bala, and prevention of recurrence during follow-up period were the parameters used to assess the overall effect of therapy. The observed data were subjected to appropriate statistical analysis for testing the statistical significance. Kasahara Dashemani provided relief in all symptoms of Kasa irrespective of Doshic involvement and on the parameters of Atura Bala. All the changes were statistically highly significant. The control group also showed similar effects which were statistically highly significant. The trial group was found to have a direct influence on serum Ig status. No patient has reported any adverse drug reactions during the treatment and follow-up periods.

Introduction: Avaleha (confection) is an unique dosage form of Ayurvedic pharmaceutics, which is frequently prescribed in various disorders and especially in respiratory disorders. Chitraka Haritaki Avaleha (CHA) is one such formulation being used extensively by Ayurveda physicians for bronchial asthma, despite its classical use in various other disorders too. CHA was first time described by Vrindamadhava in the 9 th century and had been amended for many times till today. Because of its demand, many pharmaceutical companies are also manufacturing it, and is freely available in the market. Aim: The aim is to screen and compile references pertaining to composition, method of preparation, therapeutic uses, organoleptic, and physico-chemical parameters of CHA from different classics and original research articles. Materials and methods: Description of CHA was extensively reviewed from Vrindamadhava, Chakradatta, Vangasena, Gadanigraha, Yogatarangini, Bhaishjya Ratnavali and Yogaratnakara. Synonyms, Rasapanchaka (Ayurveda principles of drug action), and Dosha Karma (therapeutic attributes) of ingredients were compiled from Bhavaprakasha Nighantu. Organoleptic and physicochemical parameters were compiled from original research articles, searched from PubMed, Google Scholar, and Research Gate. Results: Variations in formulation name, ingredients, method of preparation, therapeutic indications and Anupana (adjuvant) was observed in the classical texts. Value of water-soluble extracts and pH of analytical study was found different than Ayurveda Pharmacopeia of India standards. Conclusion: Screening through various texts revealed that CHA has been mentioned in seven classical treatises and two gazetted texts with amendments which indicate its high demand and clinical efficacy in bronchial asthma along with other diseases. Disparity found in analytical parameters indicates the need of standardization of pharmaceutical process.

Childhood period is considered as the period of rapid growth and development, as it is the crucial stage of establishing future. Gastro-intestinal disorders show high prevalence in pediatric practice. These conditions generally produce chronic illness. Grahanidosha is a disease related with Agnidushti. This condition is seen more in childhood period due to faulty dietary habit and changing lifestyle. The present paper deals with study on etiopathogenesis of Grahanidosha and evaluates the efficacy of Deavadarvyadi-Vati. The etiological factors and symptoms were observed carefully to make clear etiopathogenesis. Total 32 patients (3-12 years) were registered and randomly divided into two groups. In Group A Devadarvyadi-Vati (treated group) and in Group B Bhunimbadi-Vati (control group) given for 4 weeks with Koshna Jala. In Group A (Devadarvyadi-Vati), marked improvement was observed in 21.43% of the patients, moderate improvement was observed in 57.14% of patients and mild improvement was observed in 21.43% of patients.